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Abstract
Background: The analgesic co-proxamol (paracetamol/dextropropoxyphene combination) has been widely involved in fatal
poisoning. Concerns about its safety/effectiveness profile and widespread use for suicidal poisoning prompted its
withdrawal in the UK in 2005, with partial withdrawal between 2005 and 2007, and full withdrawal in 2008. Our objective in
this study was to assess the association between co-proxamol withdrawal and prescribing and deaths in England and Wales
in 2005–2010 compared with 1998–2004, including estimation of possible substitution effects by other analgesics.
Methods and Findings: We obtained prescribing data from the NHS Health and Social Care Information Centre (England)
and Prescribing Services Partneriaeth Cydwasanaethau GIG Cymru (Wales), and mortality data from the Office for National
Statistics. We carried out an interrupted time-series analysis of prescribing and deaths (suicide, open verdicts, accidental
poisonings) involving single analgesics. The reduction in prescribing of co-proxamol following its withdrawal in 2005 was
accompanied by increases in prescribing of several other analgesics (co-codamol, paracetamol, codeine, co-dydramol,
tramadol, oxycodone, and morphine) during 2005–2010 compared with 1998–2004. These changes were associated with
major reductions in deaths due to poisoning with co-proxamol receiving verdicts of suicide and undetermined cause of 221
deaths (95% CI 234 to 28) per quarter, equating to approximately 500 fewer suicide deaths (261%) over the 6 years 2005–
2010, and 225 deaths (95% CI 238 to 212) per quarter, equating to 600 fewer deaths (262%) when accidental poisoning
deaths were included. There was little observed change in deaths involving other analgesics, apart from an increase in
oxycodone poisonings, but numbers were small. Limitations were that the study was based on deaths involving single
drugs alone and changes in deaths involving prescribed morphine could not be assessed.
Conclusions: During the 6 years following the withdrawal of co-proxamol in the UK, there was a major reduction in
poisoning deaths involving this drug, without apparent significant increase in deaths involving other analgesics.
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In January 2005, following a review of the effectiveness and
safety profile of the analgesic co-proxamol by the UK Medicines
and Healthcare products Regulatory Agency (MHRA), the UK
Committee on Safety of Medicines (CSM) announced that the
drug should be withdrawn from use in the UK, the final date of
withdrawal being 31st December 2007. During the intervening
period (2005–2007), doctors were advised not to prescribe co-
proxamol to any new patients and to make efforts to move patients
to suitable alternative medication (although patients for whom this
was difficult could continue to receive the drug through normal
prescribing) [1,2]. The alternatives suggested for acute pain were,
first, paracetamol, secondly, the non-steroidal anti-inflammatory
drug (NSAID) ibuprofen, thirdly, a combination of the two,
fourthly, paracetamol and an alternative NSAID (with codeine or
dihydrocodeine being alternatives to NSAIDs where these were
contraindicated). Similar steps were recommended for chronic
pain, but with possible addition of codeine or dihydrocodeine to
paracetamol and an NSAID, plus use of a tricyclic antidepressant
or anticonvulsant where pain control was difficult. Where the
chronic pain was progressive, for example cancer, more potent
opioids (e.g., morphine, oxycodone) could be considered [1].
The background to these steps was longstanding concern about
the extent of fatal self-poisoning with co-proxamol [3,4]. The drug
is a combination of paracetamol (acetaminophen) and the opiate
dextropropoxyphene. Death following overdose usually occurs
because of the toxic effects of high levels of dextropropoxyphene
on respiration and cardiac conduction [5,6]. There is a relatively
narrow margin between therapeutic and potentially lethal
concentrations [7]. While concerns had been expressed over
many years about the number of deaths involving co-proxamol
[3,8], the MHRA review was prompted by research that showed
that between 1997 and 1999, co-proxamol was the single drug
used most frequently for suicide in England and Wales (with 766
deaths over the 3-y period) and was implicated in a fifth of all
drug-poisoning suicides, or approximately 5% of all suicides [4].
The MHRA also had concerns about limited efficacy of co-
proxamol, safety in therapeutic use, and abuse potential [3,9].
In June 2009, following the UK lead, the European Medicines
Agency recommended that dextropropoxyphene-containing med-
ication be withdrawn throughout the European Union [10], which
became European policy in June 2010, with full withdrawal by
September 2011. In 2009, a US Foods and Drugs Administration
(FDA) panel recommended that the FDA should withdraw
dextropropoxyphene from the US market [11], and in 2010 the
FDA instructed manufacturers to cease production [12]. Also, in
2010 all dextropropoxyphene products were withdrawn in Canada
[13].
During the 3-y withdrawal phase in the UK (2005–2007), a
major reduction in prescribing of co-proxamol was recorded in
both England and Wales [14–16] and Scotland [17]. Beneficial
effects on suicides involving co-proxamol were shown in Scotland
for 2005–2006 [17] and in England and Wales for 2005–2007
[16]. Importantly, in England and Wales no evidence of increased
poisoning deaths involving other analgesics was found, in spite of
significantly greater prescribing of some preparations, specifically
co-codamol, paracetamol, co-dydramol, and codeine. The chang-
es in England and Wales were associated with fewer suicidal and
accidental poisoning deaths involving co-proxamol over the 3-y
period [16]. In Ireland, where co-proxamol (Distalgesic) was
totally withdrawn in January 2006, there was a very marked
reduction in intentional non-fatal co-proxamol overdose presen-
tations to general hospitals between 2006 and 2008, which greatly
exceeded the increase seen in non-fatal overdoses of other
analgesics [18]. A similar finding was shown for non-fatal self-
poisoning presentations to general hospitals in England between
2005 and 2007, although there was an upturn in episodes
involving other analgesics in 2007 [19]. Thus the initial
withdrawal phase in the UK, and the total withdrawal in Ireland,
appeared not only to result in a major reduction in poisoning
deaths and non-fatal overdoses involving co-proxamol, but also
only limited substitution by fatal or non-fatal poisonings with other
analgesics.
It is important to examine longer-term effects of the initiative in
order to determine the impact of the full withdrawal of co-
proxamol and, especially, whether there has been a substitution
effect in terms of a gradual move to use of other dangerous
methods of self-poisoning [20]. The aim of the present study was
to evaluate the longer-term impact of the withdrawal of co-
proxamol in England and Wales, including the initial withdrawal
phase (2005–2007) and the first 3 y of the full withdrawal period
(2008–2010). Our evaluation has included assessment of the
impact on prescribing of analgesics and on poisoning deaths
involving co-proxamol and other analgesics. While our main focus
was on suicidal poisonings, we have also included accidental
poisoning deaths.
Method
Prescriptions
Quarterly data for 1998–2010 on prescriptions of co-proxamol,
co-codamol, codeine, co-dydramol, dihydrocodeine, NSAIDs,
paracetamol, and tramadol in England and Wales were obtained
from the NHS Health and Social Care Information Centre
(England) and Prescribing Services Partneriaeth Cydwasanaethau
GIG Cymru (Wales). Prescription data for Wales were not
available for the first quarter of 1998, so figures for this quarter
were estimated using least squares methods to extrapolate from
trend data for subsequent quarters.
We also obtained prescription data for oral morphine and for
oxycodone for England only between 1998 and 2010 (data for
Wales were unavailable for some of this period).
Deaths
Quarterly data on drug-poisoning deaths (suicides, open
verdicts, and accidental poisonings) involving co-proxamol, co-
codamol, codeine, co-dydramol, dihydrocodeine, NSAIDs, para-
cetamol, and tramadol based on death registrations during 1998–
2010 in England and Wales were provided by the Office for
National Statistics (ONS) (we also received annual death data for
oxycodone). Data were extracted from the ONS database of
deaths related to drug poisoning, which is extracted from the
national mortality database for England and Wales. Deaths are
included if the underlying cause of death is regarded as drug
related, according to the National Statistics definition [21]. Almost
all deaths on the drug-poisoning database had a coroner’s inquest.
For each death the database includes the underlying cause of
death, all other causes mentioned on the death certificate, and
every mention of a substance recorded by the coroner in the cause
of death section or elsewhere in the coroner’s certificate produced
after the inquest. For compound analgesics all the components of
the compound are mentioned, with the exception of dextropro-
poxyphene, when co-proxamol is coded whether or not paracet-
amol is mentioned, because in the UK dextropropoxyphene is
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Analyses were restricted to deaths involving single drugs, or
single drugs and alcohol. Similar data were supplied for overall
drug-poisoning deaths receiving underlying causes of death of
suicide, undetermined, or accidental poisoning. These data are
based on the coroners’ short form verdicts and, in the case of
narrative verdicts (where an account of the death is provided
rather than a short form verdict), on International Classification of
Disease (ICD) coding rules. Coroners reach their verdicts on the
basis of information from clinicians, relatives, and police, and, in
the case of poisonings, on findings of toxicological reports. In a
proportion of injury and poisoning deaths where a narrative
verdict has been returned, ONS has no indication from the
information provided by the coroner of whether the toxic
substance was self-administered or if there was deliberate intent
to self-harm. Such deaths are coded as accidental in line with ICD
coding rules [22].
In order to evaluate the impact of the withdrawal of co-
proxamol on suicide, we have used data on deaths receiving a
suicide verdict and those coded as injury or poisoning of
undetermined intent (open verdicts) by the ONS. In England
and Wales, it has been customary to assume that most of the latter
are cases where the harm was self-inflicted but there was
insufficient evidence to prove intent to die [23,24].
Statistical Analyses
Analyses of trends in prescribing and deaths were conducted
using Stata version 10.0 [25]. We used interrupted time-series
analysis to estimate changes in levels and trends in prescribing and
deaths following the CSM announcement of the withdrawal of co-
proxamol. This method controls for baseline level and trend when
estimating expected changes in the number of prescriptions (or
deaths) due to the intervention [26].
Specifically, segmented regression analysis [27] was used to
estimate the mean quarterly number of prescriptions and deaths
that might have occurred in the post-intervention period without
the CSM announcement, and the number of prescriptions and
deaths that actually occurred following the CSM announcement.
The latter were obtained from best fitted data lines from the
regressions and are better estimates than taking the average of the
actual values. The beginning of 2005 was chosen as the point of
intervention. Thus our data comprised 28 quarters in the pre-
intervention segment and 24 quarters in the post-intervention
segment. Slope and level regression coefficients were used to
estimate the mean quarterly absolute differences in prescriptions
and deaths (at the midpoint of the post-intervention period,
midway between quarter 4 of 2007 and quarter 1 of 2008).
Preliminary analyses indicated some autocorrelation in the data,
therefore the Cochrane-Orcutt autoregression procedure was used
(rather than ordinary linear regression) to correct for first order
serially correlated errors. The Durbin Watson statistic of all final
models was close to the preferred value of 2, indicating that no
serious autocorrelation remained.
Results
Prescriptions for Co-proxamol and Other Analgesics
As expected, prescribing of co-proxamol showed a marked
reduction after the beginning of the initial withdrawal. Thus there
was a step change reduction in prescribing of co-proxamol in
England and Wales during 2005–2010 compared to the trend in
prescribing during 1998–2004 (Figure 1). At the beginning of 2008
there was a further downward step in prescribing such that there
were very few prescriptions during 2008–2010. Overall between
2005 and 2010 there was a 53% reduction in prescribing of co-
proxamol compared to previous trends (Table 1). There were
significant increases in prescribing of co-codamol (+23%), para-
cetamol (+16%), codeine (+10%), co-dydramol (+6%), and
tramadol (+19%) during 2005–2010 (Figure 1; Tables 1 and S1).
There was a sharp decrease in prescribing of NSAIDs, which
began shortly before the withdrawal of co-proxamol (which was
due to safety concerns about Cox2 inhibitors [28]). There was also
a decrease in prescriptions of dihydrocodeine (210%) in 2005–
2010. Overall, when all seven analgesics (excluding co-proxamol)
were combined this showed no significant change in either level or
trend associated with the withdrawal of co-proxamol. With
NSAIDs excluded, however, there was a significant 15% increase
in prescribing of the other six analgesics combined.
Prescription data for morphine were only available for England
for the study period. Our analysis showed a significant mean
quarterly increase in the number of prescriptions of morphine
associated with the CSM announcement of 71,000 prescriptions
(95% CI 62,000–79,000), equating to a 35% increase in the period
2005 to 2010. Prescription data for oxycodone were also only
available for England for the study period. The number of
prescriptions increased steadily from very low levels (mean of
69,000 per year in 1998–2004) to a mean of 527,000 per year in
2005–2010. An interrupted time-series analysis, as was conducted
on other prescription data, did not generate meaningful estimates
because of small numbers.
Deaths Involving Co-proxamol and Other Analgesics
The numbers of deaths with suicide (including open verdicts) or
accidental poisoning verdicts between 2000 and 2010 involving
co-proxamol alone and those involving the seven other analgesics
alone (both with or without alcohol), are shown in Table 2,
together with all drug-poisoning deaths and all suicides. Between
2005 and 2010 there was a marked reduction in the numbers and
proportions of all poisoning deaths recorded as suicide that
involved co-proxamol. While the numbers of deaths involving
other analgesics receiving a suicide or open verdict also declined,
they showed a small increase in percentage of the total number of
poisoning deaths. There was a similar marked decrease in deaths
involving co-proxamol when accidental deaths were included, but
without an increase in percentage of poisoning deaths involving
other analgesics (although numbers of accidental poisonings with
other analgesics increased slightly in 2008–2010). Exclusion of
NSAIDs made little difference to the results of these analyses.
The impact of the initial withdrawal phase (2005–2007) and of
the full withdrawal (2008–2010) on deaths involving co-proxamol
and deaths involving other analgesics are shown graphically in
Figure 2. There was some reduction in deaths involving co-
proxamol in the 2 or 3 y preceding the beginning of the initial
withdrawal phase (2005–2007), then a steady marked reduction
during the initial withdrawal phase (2005–2007), with a further
smaller reduction during the first 3 y of the full withdrawal (2008–
2010). The number of deaths involving other analgesics did not
appear to change markedly during these periods.
The overall apparent beneficial changes following the with-
drawal of co-proxamol were confirmed when the data were
subjected to interrupted time series regression analyses (Table 3).
During the 2005–2010 period there was a highly significant mean
quarterly reduction in deaths involving co-proxamol alone that
received a suicide (including open) verdict (221 [95% CI 234 to
28]), and similarly when accidental deaths were included (225
[95% CI 238 to 212]). There was no significant change in deaths
involving the seven other analgesics combined. When we
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significant step or trend change associated with the withdrawal of
co-proxamol. There were increases in deaths involving co-
codamol and codeine during the overall study period, but these
began well before the withdrawal of co-proxamol. All drug-
poisoning deaths (excluding those involving co-proxamol and
other analgesics) receiving a suicide or open verdict were reduced
following the withdrawal of co-proxamol, although when acci-
dental deaths were included they showed a significant increase of
84 (95% CI 28–141) per quarter (Table 3).
The estimated reduction in deaths involving co-proxamol alone
between 1998–2004 and 2005–2010 was 61% for suicide and
Figure 1. Trends in prescriptions dispensed for co-proxamol and seven other analgesics in England and Wales, 1998–2010.
doi:10.1371/journal.pmed.1001213.g001
Table 1. Changes in prescriptions involving co-proxamol and seven other analgesics in England and Wales, 1998–2010, associated
with the Committee on Safety of Medicines (CSM) announcement in January 2005.
Prescriptions (Thousands) Estimation of the Absolute Effect during 2005–2010 of the CSM Announcement
a
Mean Quarterly Estimated
Number without CSM
Announcement
b
Mean Quarterly Estimated
Number with CSM
Announcement
b
Mean Quarterly
Change during
2005 to 2010
c (95% CIs)
d
Co-proxamol 1,018 482 2536 2941 to 2130
Co-codamol 2,762 3,402 640 554 to 726
Codeine 591 648 57 44 to 70
Co-dydramol 1,014 1,074 60 36 to 85
Dihydrocodeine 643 580 263 2105 to 222
NSAIDs 5,794 4,453 21,341 21,507 to 21,176
Paracetamol 3,222 3,745 523 288 to 759
Tramadol 1,207 1,440 233 179 to 288
Seven analgesics other than co-proxamol 10,104 10,207 103 2132 to 337
Six analgesics other than co-proxamol and NSAIDs 9,436 10,889 1,453 1,200 to 1,706
aUsing interrupted time-series segmented regression analysis where the intervention point is taken as the end of 2004 (the CSM announcement on the withdrawal of
co-proxamol, January 2005).
bEstimated for the midpoint quarter of 2005–2010. See Text S1 for method, equation (2) or (3).
cAbsolute difference of estimated number with CSM announcement and estimated number without CSM announcement, taken at the mid-point of the post-
intervention period, see Text S1 equation (4).
d95% CIs taken from Stata results or calculated according to Zhang et al. [38].
doi:10.1371/journal.pmed.1001213.t001
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included. This reduction equated to approximately 500 fewer
deaths from suicide between 2005 and 2010 than would be
expected without the withdrawal, and 600 fewer deaths when
accidental poisonings were included. As can be seen in Table 2,
during the full withdrawal phase (2008–2010) there was an
average of just 19 deaths per year (23 per year including
accidents). This figure is in contrast to 228 deaths per year during
1998–2004 (271 per year including accidents).
We have not presented data on deaths involving morphine
because ONS cannot distinguish between deaths due to oral and
intravenous administration (and between those due to morphine or
heroin). Deaths involving oxycodone alone and receiving suicide,
open, or accidental verdicts increased during the study period
from a mean of 2.3 per year between 2001 and 2004 to a mean of
8.2 per year between 2005 and 2010 (including 15 in 2010).
Discussion
We previously demonstrated an apparent beneficial effect of
withdrawal of co-proxamol in the UK in terms of deaths (suicides,
open verdicts, and accidents) in England and Wales during the
initial 3-y withdrawal phase (2005–2007) [16]. We have now
assessed the impact of the withdrawal over a 6-y period, including
the initial phase and the first 3 y of full withdrawal, against trends
for the 7 y prior to the announcement of the withdrawal. This
investigation has shown further significant changes following the
withdrawal, not only in terms of the expected reduced prescribing
of co-proxamol, but also increased prescribing of some other
analgesics suggested by the CSM as substitutes for co-proxamol
(paracetamol, co-codamol, codeine, co-dydramol, and, for pro-
gressive chronic pain, oxycodone and morphine), and also
tramadol. During 2005–2010 there was a 61% reduction in
deaths due to co-proxamol poisoning, equating to approximately
500 fewer deaths receiving suicide or open verdicts, and 600 when
accidental poisonings are included. Some of the accidental
poisonings are also likely to have been probable suicides, especially
since there has been a recent increase in narrative verdicts by
coroners, and where those responsible for coding cause of death at
the ONS have difficulty in deciding the cause from the narrative,
they are obliged by international convention to record the death as
accidental [22]. Most importantly, the major reduction in deaths
involving co-proxamol was not associated with a compensatory
overall increase in deaths due to poisoning with other analgesics
(although the number of accidental poisonings with other
analgesics increased in 2008–2010).
During the full withdrawal phase prescribing of co-proxamol did
not cease completely, presumably because of off-licence prescribing.
Also, deaths from poisoning with co-proxamol did not reach zero
(although there were just eight suicide deaths in 2010, and ten
including accidental poisonings), partly again possibly because of
off-licence prescribing, but also to residual supplies remaining in
homes, and, possibly, because of supplies being obtained through
internet sources. The acute reduction in prescribing of NSAIDs that
began just before the withdrawal of co-proxamol, due to concerns
about COX 2 inhibitors [28], would have been unlikely to have
affected the findings as NSAIDs alone are rarely implicated in
poisoning deaths, especially by suicide [29].
There was an overall reduction in poisoning deaths receiving
suicide or open verdicts in England and Wales in 2005–2010,
although this did not reach statistical significance. However,
suicides overall were not reduced, possibly because of the effects of
the recession that began in 2008 [30,31]. The increase in overall
poisoning deaths during 2005–2010 appears to be related to
increased numbers of deaths involving methadone, and also
benzodiazepines usually combined with other drugs [21].
Increased use of narrative verdicts, as noted above, may also
have contributed.
The apparent overall beneficial effects of the withdrawal of co-
proxamol in the UK are in keeping with the principle of reducing
Table 2. Suicide and open verdict deaths by all causes, and suicide, open verdict, and accidental deaths due to poisoning by all
drugs, co-proxamol alone, and seven other analgesics alone (or with alcohol) in England and Wales, 1998–2010.
Year All Causes All Drugs Co-proxamol Alone Other Analgesics
a Alone
Suicide, Open Suicide, Open
Suicide, Open,
Accidental Suicide, Open
Suicide, Open,
Accidental Suicide, Open
Suicide, Open,
Accidental
n (%)
b n (%)
b n (%)
b n (%)
b
1998 5,347 1,432 2,246 259 (18.1) 309 (13.8) 202 (14.1) 277 (12.3)
1999 5,241 1,414 2,294 260 (18.4) 316 (13.8) 207 (14.6) 279 (12.2)
2000 5,081 1,309 2,143 261 (19.9) 303 (14.1) 175 (13.4) 230 (10.7)
2001 4,904 1,279 2,180 232 (18.1) 276 (12.7) 195 (15.2) 257 (11.8)
2002 4,762 1,225 1,983 204 (16.7) 247 (12.5) 182 (14.9) 237 (12.0)
2003 4,811 1,194 1,843 188 (15.7) 218 (11.8) 166 (13.9) 237 (12.9)
2004 4,883 1,246 2,006 189 (15.2) 230 (11.5) 168 (13.5) 233 (11.6)
2005 4,718 1,154 1,926 131 (11.4) 157 (8.2) 196 (17.0) 254 (13.2)
2006 4,513 979 1,821 67 (6.8) 81 (4.4) 200 (20.4) 287 (15.8)
2007 4,322 888 1,852 52 (5.9) 61 (3.3) 151 (17.0) 209 (11.3)
2008 4,603 884 2,071 29 (3.3) 34 (1.6) 157 (17.8) 257 (12.4)
2009 4,682 898 2,185 21 (2.3) 26 (1.2) 155 (17.3) 267 (12.2)
2010 4,528 873 2,137 8 (0.9) 10 (0.5) 150 (17.2) 257 (12.0)
aOther analgesics: co-codamol, codeine, co-dydramol, dihydrocodeine, NSAIDS, paracetamol, and tramadol.
bPercentage of all drug-poisoning deaths.
doi:10.1371/journal.pmed.1001213.t002
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prevention [20]. The crucial question is whether withdrawal of a
common lethal means of suicide is associated with substitution by
other methods that nullify any beneficial effects. Other studies
examining effects of restriction of access to means for suicidal acts
have suggested that major substitution by other methods does not
necessarily occur [32,33]. Our results similarly indicate that no
significant substitution followed the UK initiative and hence this
appears to represent a success story in terms of suicide prevention.
The impact of the withdrawal of co-proxamol should, however, be
monitored further to see whether there is any compensatory
increase in deaths involving other analgesics in the longer term.
There have been other changes in availability of analgesics that
could possibly be relevant to this evaluation. One is the limitations
on pack sizes of paracetamol, legislation on which came into force
in the UK in 1998 [34]. While this measure appears to have had
an impact on the size of paracetamol overdoses, deaths, and liver
unit activity [29,35], it is unlikely to have affected the impact of the
withdrawal of co-proxamol as this occurred much later. Another
change has been the increased prescribing of opiates, especially
morphine and oxycodone. Unfortunately ONS is unable to
distinguish deaths due to intravenous administration of morphine
from oral administration (nor deaths due to morphine and heroin
because both drugs share the same breakdown pathway). It is
therefore not possible to know whether recent increased prescrib-
ing of morphine could have influenced the findings. There has
been a recent increase in poisoning deaths involving oxycodone,
but the numbers involved are relatively small so this is unlikely to
affect the general conclusions of this study. Oxycodone is
increasingly a drug of abuse [36], and hence some deaths may
be unintentional. Importantly, neither morphine or oxycodone
were recommended as first- or second-line analgesics to replace
co-proxamol, only as drugs that might be used in chronic
progressive pain, as in cancer patients [1].
Strengths and Limitations
A strength of the study is that it is based on national data and
includes reasonably long pre-intervention (7-y) and post-interven-
tion (6-y) periods. Also, the method of statistical analysis
(interrupted time-series regression) controls for baseline trends
when estimating effects of the intervention on prescribing and
deaths, which is preferable to methods such as comparison of
changes in proportions before and after the intervention.
However, estimates of overall effects do involve extrapolation
and hence are subject to some degree of uncertainty. Also,
percentage changes during the post-intervention period compared
with the pre-intervention period are based on mean quarterly
change estimates, which have associated uncertainty, and there-
fore should be interpreted with caution.
Figure 2. Deaths in England and Wales from poisoning with co-proxamol and other analgesics, 1998–2010. Suicide and open verdicts,
substances taken alone, with or without alcohol.
doi:10.1371/journal.pmed.1001213.g002
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drugs we based our mortality calculations solely on deaths
involving single analgesics alone (with or without alcohol). There
are also a considerable number of poisoning deaths involving
multiple drugs [21]. Where co-proxamol is one of the drugs it is
very likely to have been the lethal agent given its high toxicity. It is
possible therefore that our findings underestimate the full effects of
the withdrawal of co-proxamol. The increasing number of
narrative verdicts recorded by coroners in England and Wales
[22] could have influenced the findings through a small reduction
in suicide verdicts, although this would probably have equally
affected poisonings with co-proxamol and the other analgesics,
and any impact would have been included in our analysis of
suicide, open, and accidental deaths combined.
We have presented prescription data for the analgesics we have
investigated. For some analgesics, notably paracetamol and co-
codamol, sales will mainly be over-the-counter (OTC) rather than
through prescription. Comprehensive OTC sales data are
unfortunately not available; this would not, of course, affect the
validity of the mortality data.
As noted above, we were unable to investigate the impact of the
withdrawal on deaths involving morphine. However, most of such
deaths result from illicit drug use [21].
Finally, we have not been able to assess possible compensatory
increases in deaths from non-poisoning means that may have
occurred following the withdrawal of co-proxamol. This is because
of the range of other potential methods of suicide and also the
likely temporal effects of other influences, such as the economic
recession. However, since individuals often appear to show
preference for particular methods of suicide [37], it is unlikely
that any such effect would have been substantial.
Conclusions
Withdrawal of co-proxamol in the UK appears to have had
major beneficial effects on poisoning deaths involving this drug,
including suicides and accidental poisonings, with no evidence of
significant substitution by poisoning with other analgesics, in spite
of their increased prescribing. Now that prescribing of the more
toxic constituent of co-proxamol (dextropropoxyphene) has been
withdrawn throughout Europe and production has ceased in the
US and Canada the impact of this initiative should be evaluated
on a larger scale.
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Table 3. Changes in poisoning deaths involving co-proxamol, other analgesics, and all drugs, in England and Wales, 1998–2010,
associated with the Committee on Safety of Medicines (CSM) announcement in January 2005.
Cause of Death Estimation of the Absolute Effect during 2005 to 2010 of the CSM Announcement
a
Mean Quarterly Estimated
Number without CSM
Announcement
b
Mean Quarterly Estimated
Number with CSM
Announcement
b
Mean Quarterly
Change during
2005 to 2010
c (95% CIs)
d
Suicide, Open
Co-proxamol 34 13 221 234 to 28
Other analgesics
e 38 42 4 28t o1 6
Other analgesics (except NSAIDs)
e 38 40 2 210 to 13
All drugs (except co-proxamol and other analgesics) 201 181 219 249 to 10
All drugs 275 236 239 287 to 9
All causes 1,129 1,140 11 281 to 104
Suicide, Open, Accidental
Co-proxamol 40 15 225 238 to 212
Other analgesics
e 55 63 8 27t o2 4
Other analgesics (except NSAIDs)
e 54 61 7 27t o2 1
All drugs (except co-proxamol and other analgesics) 336 420 84 28 to 141
All drugs 430 499 69 27t o1 4 4
aUsing interrupted time-series segmented regression analysis where the intervention point is taken as the end of 2004 (the CSM announcement on the withdrawal of
co-proxamol, January 2005).
bEstimated for the midpoint quarter of 2005–2010. See Text S1 for method, equation (2) or (3).
cAbsolute difference of estimated number with CSM announcement and estimated number without CSM announcement, taken at the mid-point of the post-
intervention period, see Text S1 equation (4).
d95% CIs taken from Stata results or calculated according to Zhang et al. [38].
eOther analgesics include: co-codamol, codeine, co-dydramol, dihydrocodeine, NSAIDS, paracetamol, and tramadol.
doi:10.1371/journal.pmed.1001213.t003
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Background. Every year, about a million people worldwide
die by suicide. Most people who take their own life are
mentally ill. For some, stressful events have made life seem
worthless or too painful to bear. Suicide rates can be
reduced by improving the treatment of mental illness and of
stress and by limiting access to common suicide methods.
These methods differ from place to place. For example, in
England and Wales, where 4,528 suicides were recorded in
2010, drug-related poisoning is responsible for about a fifth
of all suicides. Notably, between 1997 and 1999, the
prescription analgesic (pain killer) co-proxamol, which
contains paracetamol and the opioid dextropropoxyphene,
was implicated in a fifth of drug-poisoning suicides in
England and Wales. In response to concerns about co-
proxamol’s widespread use for suicidal poisoning and its
safety/effectiveness profile, the UK Committee on Safety of
Medicines announced on January 31, 2005 that the drug
would be withdrawn completely from use in the UK by
December 31, 2007, and that between 2005 and 2007,
doctors should not prescribe co-proxamol to any new
patients and should try to move patients already taking
the drug onto other medications.
Why Was This Study Done? Public health experts need to
quantify the impact of co-proxamol withdrawal on analgesic
prescribing in England and Wales and on suicide rates. In
particular, they need to know whether its withdrawal has
increased the use of other analgesics in suicide (substitu-
tion). Reassuringly, between 2005 and 2007, there was a
reduction in both co-proxamol prescribing and in co-
proxamol–related suicides in England and Wales but no
evidence of increased poisoning deaths involving other
prescription analgesics. But what about the longer-term
effects of co-proxamol withdrawal? In this interrupted time-
series study, the researchers assess the impact of co-
proxamol withdrawal in England and Wales by comparing
data on analgesic prescribing and suicide rates collected
between 1998 and 2004 and between 2005 and 2010. An
interrupted time-series study uses serial measurements of
events in a population before and after an intervention to
look for changes in response to the intervention.
What Did the Researchers Do and Find? The researchers
obtained prescribing data from 1998 to 2010 for co-
proxamol and several other analgesics from government
sources in England and Wales, and data on suicides, open
verdicts (poisoning of undetermined intent), and accidental
poisonings involving single analgesics from the UK Office for
National Statistics. They then estimated changes in levels
and trends in prescribing and deaths following the 2005
announcement of co-proxamol withdrawal using interrupted
time-series analysis. There was a marked reduction in co-
proxamol prescribing that was accompanied by increased
prescribing of several other analgesics after co-proxamol
withdrawal. These changes were associated with a major
reduction in suicide deaths due to poisoning that equated to
500 fewer deaths occurring between 2005 and 2010 than
would have occurred had co-proxamol not been withdrawn.
On average, there were 20 co-proxamol-related deaths
(suicides and accidental poisonings) per year during 2008–
2010 compared to more than 250 per year in the 1990s.
Finally, there was little evidence of a change in the number
of deaths involving other analgesics after co-proxamol
withdrawal except for a small increase in the number of
deaths involving the opioid oxycodone.
What Do These Findings Mean? These findings show
that, during the six years that followed the beginning of the
phased withdrawal of co-proxamol in the UK, there has been
a major reduction in poisoning deaths involving this drug in
England and Wales. The findings provide little evidence for
an increase in deaths involving other analgesics. However,
because the Office of National Statistics does not distinguish
between deaths due to oral and intravenous morphine or
between deaths due to morphine and heroin, the research-
ers did not assess whether there have been any changes in
deaths involving morphine since 2005. Moreover, this study
did not assess suicides related to the use of multiple drugs or
investigate whether suicides involving methods other than
drug-related poisoning have increased since co-proxamol
withdrawal. Despite these limitations, these findings suggest
that the withdrawal of co-proxamol in the UK and possibly
elsewhere should have major beneficial effects on suicide
rates, at least in the relatively short term.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001213.
N The World Health Organization provides information on
the global burden of suicide and on suicide prevention (in
several languages)
N The US National Institute of Mental Health provides
information on suicide and suicide prevention web page
N The UK National Health Service Choices website has
detailed information about suicide and its prevention
N The University of Oxford Centre for Suicide Research
provides information about co-proxamol and suicide and
links to other research on suicide
N The 2005 announcement of the withdrawal of co-proxamol
in the UK is available through the UK Medicines and
Healthcare products Regulatory Agency, which also
provides a question and answer document about the
risks and benefits of co-proxamol
N MedlinePlus provides links to further resources about
suicide (in English and Spanish)
N The charity Healthtalkonline has personal stories about
dealing with suicide
N Help is at Hand is a resource for people bereaved by
suicide
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